20/20 Biolabs (AIDX) Stock Overview

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. More details

AIDX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 62.1% per year over past 5 years

Shares are highly illiquid

Does not have a meaningful market cap ($29M)

+ 1 more risk

AIDX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

20/20 Biolabs, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for 20/20 Biolabs
Historical stock prices
Current Share Price	US$2.71
52 Week High	US$50.00
52 Week Low	US$2.51
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-88.64%

Recent updates

Shareholder Returns

	AIDX	US Medical Equipment	US Market
7D	-18.9%	-4.7%	-0.6%
1Y	n/a	-8.0%	21.7%

Return vs Industry: Insufficient data to determine how AIDX performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how AIDX performed against the US Market.

Price Volatility

Is AIDX's price volatile compared to industry and market?
AIDX volatility
AIDX Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.2%
Market Average Movement	6.7%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: AIDX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AIDX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	19	Jonathan Cohen	2020biolabs.com

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market.

20/20 Biolabs, Inc. Fundamentals Summary

How do 20/20 Biolabs's earnings and revenue compare to its market cap?
AIDX fundamental statistics
Market cap	US$28.97m
Earnings (TTM)	-US$3.26m
Revenue (TTM)	US$2.04m

13.7x

P/S Ratio

-8.6x

P/E Ratio

Is AIDX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AIDX income statement (TTM)
Revenue	US$2.04m
Cost of Revenue	US$1.39m
Gross Profit	US$655.75k
Other Expenses	US$3.91m
Earnings	-US$3.26m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.31
Gross Margin	32.10%
Net Profit Margin	-159.33%
Debt/Equity Ratio	415.4%

How did AIDX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/11 21:31
End of Day Share Price	2026/03/11 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

20/20 Biolabs, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

20/20 Biolabs, Inc.NasdaqCM:AIDX Stock Report